Cytoreductive surgery and perioperative intraperitoneal chemotherapy for gynecological malignancies: a single center experience

Introduction: The objective of this study was to assess the outcome of cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) plus early postoperative intraperitoneal chemotherapy (EPIC) in patients with advanced gynecological malignancies. Materials and Methods: A retrospective series of 51 patients with advanced gynecologic cancer, evaluated between May 2008 to February 2014. Peritoneal Cancer Index (PCI) and Completeness of Cytoreduction (CCR) score were used in the study group. The study group consisted of the cancers of ovarian, fallopian tube, endometrial, and uterine sarcomas. Results: Mean PCI score of the study group was 18, and the postoperative complications were similar with the literature. Patients were followed in a period of 15 days to 64 months and the mean survival time was 22.8 months. Fifty-two percent of the patients were alive without evidence of the disease and overall one-year survival was found 56%. Conclusions: The authors concluded that CRS, HIPEC, EPIC, and peritonectomy are a crucial options in patients with advanced gynecological cancers.

Cytoreductive surgery; HIPEC: EPIC; Peritonectomy.

[1] Königsrainer I., Horvath P., Struller F., Grischke E.M., Wallwiener D., Königsrainer A., Beckert S.: “Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in recurrent epithelial ovarian cancer with peritoneal metastases: a single centre experience”. Langenbecks Arch. Surg., 2014, 399, 589.

[2] Robella M., Vaira M., Marsanic P., Mellano A., Borsano A., Cinquegrana A., et al.: “Treatment of peritoneal carcinomatosis from ovarian cancer by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC)”. Minerva Chir., 2014, 69, 27.

[3] Abu-Zaid A., Azzam A.Z., AlOmar O., Salem H., Amin T., Al-Badawi I.A.: “Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for managing peritoneal carcinomatosis from endometrial carcinoma: a single-center experience of 6 cases”. Ann. Saudi Med., 2014, 34, 159.

[4] Liu Y., Endo Y., Fujita T., Ishibashi H., Nishioka T., Canbay E., Li Y., Ogura S.I., Yonemura Y.: “Cytoreductive surgery under aminolevulinic acid-mediated photodynamic diagnosis plus hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from ovarian cancer and primary peritoneal carcinoma: results of a phase I trial”. Ann. Surg. Oncol., 2014, 21, 4256. doi: 10.1245/s10434-014-3901-5. Epub 2014 Jul 24..

[5] Vizzielli G., Costantini B., Tortorella L., Petrillo M., Fanfani F., Chiantera V., et al.: “Influence of intraperitoneal dissemination assessed by laparoscopy on prognosis of advanced ovarian cancer: an exploratory analysis of a single-institution experience”. Ann. Surg. Oncol., 2014, 21, 3970. doi: 10.1245/s10434-014-3783-6. Epub 2014 May 22.

[6] Sugarbaker P.H.: “Peritonectomy procedures”. Ann. Surg., 1995, 221, 29.

[7] Cavaliere F., Giannarelli D., Valle M., Federici O., Liotta G., Perri P., et al.: Peritoneal carcinomatosis from ovarian epithelial primary: combined aggressive treatment”. In Vivo, 2009, 23, 441.

[8] Verwaal V.J., Bruin S., Boot H., van Slooten G., van Tinteren H.: “8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in pa-tients with peritoneal carcinomatosis of colorectal cancer”. Ann. Surg. Oncol., 2008, 15, 2426.

[9] Elias D., Lefevre J.H., Chevalier J., Brouquet A., Marchal F., Classe J. M., et al.: “Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin”. J. Clin Oncol 2009, 27, 681. doi: 10.1200/JCO.2008.19.7160. Epub 2008 Dec 22.

[10] Franko J., Ibrahim Z., Gusani N.J., Holtzman M.P., Bartlett D.L., Zeh H.J. 3rd.: “Cytoreductive surgery and hyperthermic intraperi-toneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis”. Cancer, 2010, 116, 3756.

[11] Chua T.C., Morris D.L., Saxena A., Esquivel J., Liauw W., Doerfer J., et al.: “Influence of modern systemic therapies as adjunct to cytoreduction and perioperative intraperitoneal chemotherapy for patients with colorectal peritoneal carcinomatosis: a multicenter study”. Ann. Surg. Oncol., 2011, 18, 1560.

[12] Sugarbaker P.H.: “Cytoreductive surgery and perioperative intraperitoneal chemotherapy for the treatment of advanced primary and recurrent ovarian cancer”. Curr. Opin. Obstet. Gynecol., 2009, 21, 15.

[13] Sugarbaker P.H.: “Cytoreductive surgery and perioperative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome”. Eur. J. Surg. Oncol., 2001, 27, 239.

[14] Jayne D.G., Fook S., Loi C.: “Peritoneal carcinomatosis from colorectal cancer”. Br. J. Surg., 2002, 89, 1545.

[15] Glehen O., Osinski D., Cotte E.: “Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures”. Ann. Surg. Oncol., 2003, 10, 863.

[16] Stephens A.D., Alderman R., Chang D.: “Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyper-thermic intraoperative itraperitoneal chemotherapy using the coliseum technique”. Ann. Surg. Oncol., 1999, 6, 790.

[17] Sugarbaker P.H.: “Comprehensive management of peritoneal surface malignancy using cytoreductive surgery and perioperative intraperitoneal chemotherapy: the Washington Cancer Institute approach”. Expert Opin. Pharmacother., 2009, 10, 1965.

[18] Begossi G., Gonzalez-Moreno S., Ortega-Perez G., Fon L.J., Sugarbaker P.H.: “Cytoreduction and intraperitoneal chemotherapy for the management of peritoneal carcinomatosis, sarcomatosis and mesothelioma”. Eur. J. Surg. Oncol., 2002, 28, 80.

[19] Feldman A.L., Libutti S.K., Pingpank J.F., Bartlett D.L., Beresnev T. H., Mavroukakis S.M., et al.: “Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy”. J. Clin. Oncol., 2003, 21, 4560.

[20] Yan T.D., Edwards G., Alderman R., Marquardt C.E., Sugarbaker P. H.: “Morbidity and mortality assessment of cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma—a prospective study of 70 consecutive cases”. Ann. Surg. Oncol., 2007, 14, 515.

[21] Chua T.C., Yan T.D., Morris D.L.: “Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: the Australian experience”. J. Surg. Oncol., 2009, 99, 109.

[22] Young R.C., Perez C.A., Hoskins W.J.: “Cancer of the ovary”. In: De Vita V.T., Hellman S., Rosenberg S.A. (eds). Cancer: principles and practice of oncology. 4th ed. Philadelphia, Pa: Lippincott-Raven, 1993, 1226.

[23] Glehen O., Osinsky D., Cotte E., Kwiatkowski F., Freyer G., Isaac S., et al.: “Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures”. Ann. Surg. Oncol., 2003, 10, 863.

[24] Karadayi K., Turan M., Karadayi S., Alagozlu H., Kilickap S., Buyukcelik A., et al.: “Cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy: morbidity and mortality analysis of our patients”. Turkiye klinikleri tip bilimleri dergisi, 2012, 32, 162.

[25] Baratti D., Kusamura S., Mingrone E., Balestra M.R., Laterza B., Deraco M.: “Identification of a subgroup of patients at highest risk for complications after surgical cytoreduction and hyperthermic intraperitoneal chemotherapy”. Ann. Surg., 2012, 256, 334.

[26] Karadayi K., Turan M., Sen M.: “A new technique for partial splenectomy with radiofrequency technology”. Surg. Laparosc. Endosc. Percutan. Tech., 2011, 21, 358.

[27] Griffiths C.T.: “Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma”. Natl. Cancer Inst. Monogr., 1975, 42, 101.

[28] Benoit L., Cheynel N., Ortega-Deballon P., Giacomo G.D., Chauffert B., Rat P.: “Closed hyperthermic intraperitoneal chemotherapy with open abdomen: a novel technique to reduce exposure of the sur-gical team to chemotherapy drugs”. Ann. Surg. Oncol., 2008, 15, 542.

[29] Plaisant N., Quenet F., Fabbro M., Gourgou S., Gutowski M., Saint Aubert B., Rouanet P.: “Secondary debulking surgery and intraperitoneal chemotherapy in advanced or recurrent epithelial ovarian cancer”. Gynecol. Obstet. Fertil., 2004, 32, 391.

[30] Piso P., Dahlke M.H., Loss M., Schlitt H.J.: “Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer”. World. J. Surg. Oncol., 2004, 2, 21.

[31] Ryu K.S., Kim J.H., Ko H.S., Kim J.W., Ahn W.S., Park Y.G., et al.: “Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer”. Gynecol. Oncol., 2004, 94, 325.

[32] Rufián S., Muñoz-Casares F.C., Briceño J., Díaz C.J., Rubio M.J., Ortega R., et al.: “Radical surgery, peritonectomy and intraoperative intraperitonealchemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer”. J. Surg. Oncol., 2006, 94, 316.